The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity
Source: Streetwise Reports (03/20/2026)

Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts.

Biotech Company Accelerates AI Detection Breakthrough Globally
Source: Streetwise Reports (03/20/2026)

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) advanced AI-powered screening kiosks, targeting safer operations across industrial sectors.

Life Sciences Firm Advances Massive US$2.4B Market Opportunity
Source: Streetwise Reports (03/18/2026)

Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii.

Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA).

Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch
Source: Andrew Fein (03/16/2026)

H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market.